PAM
NAMS icon

Pamalican Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

Pamalican Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$771K – 27
2024
Q4 		$771K Buy
+30,000
New +$637K 0.34% 32

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Pamalican Asset Management's NAMS Position: Q1 2025 in Review

Pamalican Asset Management sold out of NewAmsterdam Pharma (NAMS) in Q1 2025, closing a stake of 30,000 shares — an estimated $771K sold.

Pamalican Asset Management first reported a position in NAMS in Q4 2024 and held it in 1 quarter. The position peaked at $771K in Q4 2024. 126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • Pamalican Asset Management reported no remaining NewAmsterdam Pharma position as of Q1 2025 after selling out during the quarter.
  • Pamalican Asset Management sold 30,000 NewAmsterdam Pharma shares in Q1 2025, an estimated $771K.
  • Pamalican Asset Management first reported a position in NewAmsterdam Pharma in Q4 2024 and held it in 1 quarter.
  • Pamalican Asset Management's NewAmsterdam Pharma position peaked at $771K in Q4 2024.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on Pamalican Asset Management's 13F filing for Q1 2025, filed 9 May 2025.